Artemin和Ki-67在乳腺浸润性导管癌分子病理分型中的临床意义

目的:探讨乳腺浸润性导管癌的临床病理分型与病理特征的关系及其对预后的影响。方法:回顾性分析2013年1月至2013年6月我院收治的287例乳腺浸润性导管癌患者病理资料。结果:乳腺浸润性导管癌患者分型:Luminal A型20例（7.0%），Luminal B型156例（54.4%），HER-2过表达型69例（24.0%），三阴型42例（14.6%）；Luminal B型中HER-2阴性65例（41.7%），HER-2阳性91例（58.3%）。乳腺浸润性导管癌病理分型在患者年龄、绝经状态、病理分级、TNM分期、Artemin等因素中的分布差异明显，具有统计学意义（P＜0.05）。 Luminal B型乳腺癌患者多呈现病理分级高（II级以上占86.5%），分期高（II期以上占60.9%）等特点。结论:临床病理分型是针对乳腺癌个体方案治疗的重要依据，对判断预后有重要的价值。

The clinical pathological significance of Artemin and Ki-67 in moleculartype type in in-filtrating ductal carcinoma of breast

Objective:To explore the clinic pathological characters and pathological type in breast invasive ductal carcinoma,and predict value of prognosis. Methods:Total 287 cases of breast invasive ductal carcinoma were analyzed retrospectively. Results:The cases have been divide into Luminal A,Luminal B,HER-2 over express and triple-negative. Luminal A positive in 20 cases(7. 0%),Luminal B positive in 156 cases(54. 4%),HER-2 over express 69 cases(24. 0%),triple-negative 42 cases(14. 6%). In subtype of Luminal B,HER-2 positive were 91 cases (58. 3%)and negative 65 cases(41. 7%). The subtype of breast invasive ductal carcinoma was associated with age, menopausal status,pathological grade,TNM stage,and protein artemin(P<0. 05). Most of Luminal B was later in grade(86. 5% cases were more than Ⅱ grade)and stage(60. 9% cases were more than Ⅱ stage). Conclusion:Clin-ical pathological type is important for individual therapy for breast invasive ductal carcinoma and have great value for prognosis.